Aims Inpatients with heart failure and renal impairment have poor outcomes and variable quality of care. We investigate treatment practice and outcomes in an unselected real-world cohort using historical creatinine measurements. Methods and results Admissions between 1/4/2013 and 30/4/2015 diagnosed at discharge with heart failure were retrospectively analysed. Stages of chronic kidney disease (CKD) and acute kidney injury (AKI) were calculated from creatinine at discharge and 3-12 months before admission. We identified 1056 admissions of 851 patients (mean age 76 years, 56% Caucasian, 36% with diabetes mellitus, 54% with ischaemic heart disease, and 57% with valvular heart disease). CKD was common; 36%-Stage 3a/b, 11%-Stage 4/5; patients were older, more often diabetic, with higher potassium, lower haemoglobin, and more oedema but similar prevalence of left ventricular systolic dysfunction (LVSD) compared patients with Stages 0-2. AKI was present in 17.0% (10.4%-Stage 1, 3.7%-Stage 2, and 2.9%-Stage 3); these had higher potassium and lower haemoglobin than patients with no AKI. Length of stay was longer in Stage 4/5 CKD [11 days; P = 0.008] and AKI [13 days; P = 0.006]. Mortality was higher with Stage 4/5 CKD (13.8% compared with 7.7% for Stages 0-2 CKD (P = 0.036)] and increased with AKI (5%-no AKI, 20.9%-Stage 1, 35.9%-Stage 2, and 48.4%-Stage 3; P < 0.001). Adjusted for age, diabetes, and LVSD, both AKI and Stage 4/5 CKD were independent predictors of in-hospital mortality. In survivors with LVSD, the discharge prescription of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers decreased with progressive CKD, [84%-no-mild, 59%-moderate, and 36%-severe CKD; P < 0.001]; this was not purely explained by hyperkalaemia. Conclusions Inpatients with heart failure and renal impairment, acute and chronic, failed to receive recommended therapy and had poor outcomes.
Introduction
Heart failure is a significant and growing public health problem. In England, over the year 2014-15, there were 764 977 admissions coded with heart failure as a diagnosis, with 70 890 of them in the first diagnostic position. 1 Whilst progress has been made with prognosis-modifying therapies in heart failure with left ventricular systolic dysfunction (LVSD), cases where ejection fraction is apparently preserved and where patients have multiple comorbidities remain a management challenge. The National Heart Failure Audit for England and Wales revealed that patients had poor but still highly variable outcomes; patients aged <75 years and those managed on cardiology wards had a lower mortality of approximately 5%, compared with over 15% in other groups. 2 Renal impairment on admission in patients admitted with heart failure is common, present in approximately half, and associated with high mortality. [3] [4] [5] Similarly, worsening renal failure during acute admissions with heart failure is associated with increased length of stay, high cost, and up to eight-fold higher mortality. 6, 7 However, the cause of poor outcome associated with renal impairment in heart failure patients is unclear. The neurohumoral signalling pathways and bidirectional haemodynamic interplay between the heart, the kidney, and therapy for heart failure in the healthy and impaired functional state are complex, and it has been observed that differing degrees, reversibility, and underlying causes of renal impairment have different prognostic implications. 8, 9 Previous studies have had a heterogeneous definition for renal impairment, with few using a historical (pre-admission) creatinine to assess chronicity of renal impairment.
Trials of treatments in heart failure often exclude patients with chronic kidney disease (CKD), leaving the evidence-base in this area relatively poor. 10 Consequently, national and international guidelines and recommendations are required to extrapolate the beneficial impact of disease-modifying therapies and leave a degree of the decision-making in the hands of the clinicians. [11] [12] [13] [14] It has been demonstrated that adherence to recommendations regarding prescription of disease-modifying therapies is variable and is impacted by renal function in trial settings. 2, 15, 16 It is not well known what impact renal impairment has on prescribing in current clinical practice, particularly when such patients are managed by non-cardiologists and non-nephrologists. In this study, we examine outcomes and prescribing practices in heart failure patients with and without renal impairment, using historic baseline creatinine measurements, in a hospital-wide cohort of patients from a multi-ethnic, inner-city community.
Methods

Patient identification and data collection
We undertook detailed analysis of data submitted from one hospital trust in England to the National Heart Failure Audit from April 2013 to April 2015 inclusive. These were retrospectively collected data on unscheduled admissions to an inner city UK teaching hospital coded on discharge with a primary diagnosis of heart failure or its accepted equivalents. Data were collected in accordance with the National Heart Failure Audit 2, 17 to which the trust submitted 98% of the Hospital Episodes Statistics (HES) registered primary heart failure diagnosis 2013-14. 18 LVSD was defined by left ventricular ejection fraction of <40%. Loop diuretic doses were converted into furosemide equivalents, for example 1 mg of Bumetinide is equivalent to 40 mg of Furosemide.
Renal function data
Creatinine levels on discharge had been recorded routinely using the audit tool. 18 Additionally, a prior baseline creatinine level was obtained from electronic patient notes; the latest reading that was more than 3 months but less than 12 months prior to admission. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal disease (MDRD) formula 19 and converted to CKD stages using the Kidney Disease Improving Global Outcomes criteria. 20 Severity of acute kidney injury (AKI) was determined by degree of acute change from baseline creatinine to discharge creatinine using the Kidney Disease Improving Global Outcomes criteria. 21 Data clean-up and imputation of missing values Patients discharged outside the specified time criteria and true duplicate entries were removed (10 admissions total). Special attention was paid to ensure no duplication of in-hospital death was recorded. Where a baseline creatinine was unavailable, there was assumed to be no CKD (Stage 0). In these cases, an AKI was assumed in the presence of a discharge creatinine above the normal range with the stage of AKI estimated based on the degree of elevation. Missing data from other variables were not imputed; if data were transformed to a dichotomous category, missing data points were coded as not being present. Where statistical analysis is made on a subset of the data, this is indicated in the relevant results section.
Statistical analysis
Mean, standard deviation (SD), and interquartile range (IQR) were determined for quantitative variables, frequency, and percentages for categorical variables. The inferential statistical analyses performed were independent samples t-tests for quantitative variables comparing two groups, one-way ANOVA tests comparing more than two groups and Pearson χ 2 tests for categorical variables. Two-sided P-values were calculated with a value of <0.05 considered statistically significant. Binomial logistic regression was performed for in-hospital mortality.
Results
Demographics and general observations
During the period April 2013-April 2015 inclusive, there were 1056 episodes where patients were discharged with a primary diagnosis of heart failure. These episodes relate to 851 individual patients, revealing a cohort of patients with repeated admissions during the investigated time frame. Baseline data for these individual patients are as follows. There were marginally more men (55.8%) than women, overall the population was elderly (mean age 75.9 years, SD 13.4), and multi-ethnic, with 56.4% White and the remaining 43.6% of non-Whites [a spread of Asian (16.9%), Black Kidney failure in heart failure patients 577 (12.2%), and other (14.5%)]. Over a third of patients had diabetes mellitus (36.2%), and over half of patients had ischaemic heart disease (54.5%), valvular heart disease (57.3%), and hypertension (63.6%). Considering the main place of care for the total number of admissions, the large majority of patients were cared for on General Medical wards (61.7%) with 31.7% on specialist cardiology wards.
Chronic kidney disease
Baseline creatinine readings were available in 954 admissions (90.3%). Those with no recorded baseline were assumed to have CKD Stage 0 or 1 (eGFR > 90 mL/min/1.73m
2 ). Prevalence and mortality figures for the stages of CKD are shown in Table 1 . Approximately 75.28% of admissions had a baseline eGFR of <90 mL/min/1.73 m 2 , and 47.35% had an eGFR of<60 mL/min/1.73m
2 . Approximately 10.98% of admissions had an eGFR<30 mL/min/1.73m
Admissions were grouped into three broader categories of CKD; no-mild CKD (Stages 0, 1, and 2), moderate (Stages 3a and 3b), and severe CKD (Stages 4 and 5). Characteristics are detailed in Table 2 . The no-mild CKD patients were the youngest (73.84 years) compared with moderate CKD (79.01 years) and severe CKD (78.27 years). Haemoglobin levels decreased as CKD severity advanced (no-mild CKD 12.3 g/L, moderate CKD 11.4 g/L, and severe CKD 10.3 g/L), whilst mean serum potassium concentration [K + ] increased as CKD stage advanced (no-mild CKD 4.2 mmol/L, moderate 4.4 mmol/L, and severe 4.6 mmol/L). The highest proportion of patients with moderate-severe oedema was in the moderate CKD group (61.8%). There was no difference between the three groups regarding worse symptoms of breathlessness (New York Heart Association grading III-IV), or percentage with LVSD. There were fewer patients with diabetes mellitus in the no-mild CKD group (27.1%) compared with the moderate (49.2%) and severe groups (58.6%). Blood pressure parameters were poorly recorded with almost 50% of cases missing, but there was a suggested trend towards higher blood pressure as severity of CKD worsened. There was no statistically significant difference between the proportions of patients managed on a cardiology ward.
Discharge medications (analysed in survivors to discharge)
Medications that were prescribed on discharge were analysed only in those patients that survived to discharge. The group of medications specifically recommended for patients with LVSD-angiotensin-converting enzyme (ACE)-Inhibitors, angiotensin receptor blockers (ARB), beta-blockers, and mineralocorticoid receptor antagonists (MRA)-were only analysed in those patients known to have LVSD. Diuretic dose (converted to Furosemide dose equivalents) was analysed in all survivors regardless of LVSD. There were a total of 555 admissions comprising survivors to discharge with LVSD, 288 had no-mild CKD, 209 had moderate, and 58 had severe CKD. The percentage of patients prescribed on discharge an ACE/ARB, MRA, or 'triple therapy' (ACE/ARB, MRA, and betablocker prescribed simultaneously) fell as the degree of CKD worsened, but there was no statistically significant difference between the CKD groups when comparing beta-blocker prescription or digoxin prescription ( Figure 1) . Diuretic dose was significantly lower in the no-mild CKD group compared with the moderate group and severe group, but the difference between the moderate and severe groups was non-significant ( Table 2 ).
The influence of hyperkalaemia on ACE or ARB and MRA prescription
The number of cases of survivors to discharge with LVSD being prescribed ACE/ARB or MRA was analysed according to serum potassium concentration [K + ], using different thresholds of [K + ] ( Table 3) . As the threshold potassium was increased, the percentage of cases not prescribed ACE/ARB increased in both patients with eGFR > 60 mL/min/1.73m 2 and eGFR < 60 mL/min/1.73m 2 ( Figure 2) . With MRA prescription, the percentages of cases not prescribed MRA on discharge were more static with lower thresholds of potassium but an increasing percentage were not prescribed 6 (11) 8 (14) 11 (14) No-mild vs. moderate,
No-mild vs. severe, 
Acute kidney injury
Approximately 17.0% of admissions had an AKI ( Table 4) . Severe AKI was not common overall (10.4% of total admissions had Stage 1 AKI, 3.7% had Stage 2 AKI, and 2.9% Stage 3 AKI). The presence of any AKI stratified by CKD grouping is shown in Table 2 . More significant AKI The total number of recorded deaths during the same hospital admission was 96 (9.1% of admissions). The death rate increased as CKD stage advanced ( Table 2 ). The presence of an AKI was associated with a profound increase in mortality correlating to the degree of severity of AKI ( Table 4) .
A logistic regression was performed to ascertain the effects of age, diabetes, LVSD, AKI, and severe CKD (eGFR < 30 mL/min/1.73m 2 ) on the likelihood on in-hospital death. AKI and CKD remained independent predictors of inhospital death ( Table 5) .
Patients with no-mild CKD had a tendency towards a shorter median length of stay of 6 days compared with 8 days for moderate and 11 days for severe ( Table 2) . Patients with AKI had significantly longer length of hospital stay; 12.68 days (IQR 13) compared with 9.91 days (IQR 12) without AKI P = 0.006.
The baseline CKD stage was analysed in the individual patients (851) from their first admission ( Table 2 ). The number of total admissions with heart failure for each individual patient during the study time frame was analysed according to this first presenting CKD stage. There were more readmissions in the more advanced CKD groups compared with no-mild CKD ( Table 2) .
The use of ACE-I/ARB in admissions with LVSD was more common than in admissions with no LVSD (70.66% vs. 54.23%; P < 0.001). Similarly, admissions with LVSD were more likely to be on beta-blockers (84.27% vs. 64.52%; P < 0.001) and MRA (46.23% vs. 14.59%; P < 0.001) at discharge. Serum potassium was similar between admissions with and without LVSD (4.35 ± 0.60 vs. 4.30 ± 0.66 mmol/L; P = 0.0260). Inpatient mortality was also similar between the two groups (10.26% vs. 10.64%; P = 0.850).
Discussion
This observational analysis of a large real-world cohort of patients with heart failure using pre-admission creatinine readings demonstrates adverse outcomes in the presence of renal impairment, both acute and chronic, particularly mortality. Both severe CKD and AKI were independent predictors of mortality. The length of stay was longer in severe CKD and AKI patients. Readmission rates were higher in patients with moderate CKD. Detailed analysis of medications on discharge highlights the lack of use of evidenced-based therapy in LVSD and in a significant proportion of cases these therapies were not used despite the levels of potassium being safe.
Some unexpected results merit discussion. To see higher rates of AKI in no CKD is counter-intuitive. It is possible that these are milder grades of AKI. It is increasingly recognized that the relationship between acute renal impairment and outcomes is more complex than first thought. Prognosis does not simply depend on a single time-point creatinine above the normal range but has been shown to be complex than this. 7 Similarly, it has been suggested that not all episodes of AKI confer the same poor outcomes on a population with heart failure 9 ; rising creatinine in response to commencement of ACE/ARB has different prognostic implications compared with sepsis-related AKI, but these cannot be distinguished in this retrospective data analysis. Furthermore, the apparently lower mortality in CKD Stage 5 is unanticipated. Low mortality in CKD Stage 5 may represent a population of dialysis-dependent patients admitted for fluid removal and discharged, though the mortality is higher in the long run. 22 Those with CKD Stage 5 are also younger, and many fewer numbers mean the statistical influence of individual patients is much greater. The blood pressure findings with progressive CKD are also unexpected. One traditional explanation for renal impairment in heart failure is hypoperfusion of the renal parenchyma due to low systolic blood pressures. This study has shown the blood pressures are greater in worse CKD, which could be related to the lower proportion taking an ACE/ARB or may suggest that a more complex pathogenic mechanism is at work.
Some important points must be made about the limitations of these data, such as absence of data on blood pressure at admission. In addition to the recognized inherent What is highly significant is the poorer take-up in prescription of some potentially disease-modifying medicines (ACE/ARB and MRA) for LVSD in patients with increasing CKD. Clearly, given that the evidence base for these medications in this subgroup of patients is poorer and there is a real risk of significant side-effects, notably hyperkalaemia, prescribing practices in individual cases may well deviate from best practice guidelines. However, this study demonstrates that a significant proportion of patients with eGFR < 60 mL/min/ 1.73m 2 with a potassium level, at least on discharge, well within the normal range were not prescribed an ACE/ARB (45.9%) or MRA (65.6%). The possibility is raised that in cases of moderate-severe CKD, potentially beneficial medications may be being inappropriately withheld. This analysis needs repeating on a larger scale to ensure these findings are representative of wider practice. In addition, further qualitative work needs to be performed to assess the reasons for non-prescription of recommended therapies, which may include, as well as predictable clinical contra-indications, non-documented 'contextual factors' 23 as well as physician factors such as lack of expertise in non-specialists. 16 Additionally, further randomized controlled trials are needed that include patients with more advanced CKD to ascertain the benefit of potentially disease-modifying therapies, 24 and there is a potential role for the novel potassium binders in those cases where hyperkalaemia is preventing their use. 25 Meanwhile, consideration should be given to augmenting national audit datasets with more details on renal function to capture temporal variation. The routine inclusion of nephrologists in the specialist heart failure multidisciplinary team may allow a more nuanced assessment of the risks and benefits of different management strategies in this group of patients that continue to represent a very real management challenge.
Conclusions
In conclusion, this study in multi-ethnic, inner-city, heart failure patients re-established association of chronic and acute renal impairment with poor outcome and suboptimal medical therapy, highlighting the need for multidisciplinary approach and better evidence for treatment, to improve morbidity and mortality.
